Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations
dc.contributor.author | Scheiman, James M. | en_US |
dc.contributor.author | Cryer, B. | en_US |
dc.contributor.author | Asaka, M. | en_US |
dc.contributor.author | Berenbaum, F. | en_US |
dc.contributor.author | Bonnet, J. | en_US |
dc.contributor.author | Chan, Francis K. L. | en_US |
dc.contributor.author | Krejs, G. | en_US |
dc.contributor.author | Lanas, Angel | en_US |
dc.contributor.author | Weaver, A. | en_US |
dc.contributor.author | Zerbib, F. | en_US |
dc.date.accessioned | 2010-06-01T21:30:10Z | |
dc.date.available | 2010-06-01T21:30:10Z | |
dc.date.issued | 2005-09 | en_US |
dc.identifier.citation | SCHEIMAN, J. M.; CRYER, B.; ASAKA, M.; BERENBAUM, F.; BONNET, J.; CHAN, F. K.-L.; KREJS, G.; LANAS, A.; WEAVER, A.; ZERBIB, F. (2005). "Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations." Alimentary Pharmacology & Therapeutics Symposium Series 1(1): 26-32. <http://hdl.handle.net/2027.42/74559> | en_US |
dc.identifier.issn | 1746-6334 | en_US |
dc.identifier.issn | 1746-6342 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74559 | |
dc.format.extent | 74606 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2005 Blackwell Publishing Ltd | en_US |
dc.title | Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationother | * Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan | en_US |
dc.contributor.affiliationother | † Faculty of Medicine Pierre and Marie Curie, Department of Rheumatology, Saint-Antoine Hospital, Paris, France | en_US |
dc.contributor.affiliationother | † Cardiology and Vascular Diseases Department, Victor Segalen University, Bordeaux, France | en_US |
dc.contributor.affiliationother | § Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, China | en_US |
dc.contributor.affiliationother | ¶ Karl-Franzens University, Graz, Austria | en_US |
dc.contributor.affiliationother | ** Gastroenterology Department, HCU, Instituto Aragones de Ciencias de la Salud (Red C03/02), Zaragoza, Spain | en_US |
dc.contributor.affiliationother | †† University of Nebraska Medical Center, Omaha, NE, USA | en_US |
dc.contributor.affiliationother | †† Department of Gastroenterology, Saint-Andre Hospital, Bordeaux, France | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74559/1/j.1746-6342.2005.00018.x.pdf | |
dc.identifier.doi | 10.1111/j.1746-6342.2005.00018.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics Symposium Series | en_US |
dc.identifier.citedreference | 1 Heartwire News. February 19, 2005, http://www.theheart.org. | en_US |
dc.identifier.citedreference | Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809 – 17. | en_US |
dc.identifier.citedreference | Juni P, Nartey L, Reichenbach L, et al. Risk of cardiovascular events with rofecoxib: cumulative meta-analysis. Lancet 2004; 364 ( 9450 ): 2021 – 9. | en_US |
dc.identifier.citedreference | 4 FDA Press Release. April, 2005, http://www.fda.gov/cder/drug/advisory/COX2.htm. | en_US |
dc.identifier.citedreference | Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092 – 102. | en_US |
dc.identifier.citedreference | LÉvesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481 – 9. | en_US |
dc.identifier.citedreference | Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071 – 80. | en_US |
dc.identifier.citedreference | Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787 – 96. | en_US |
dc.identifier.citedreference | Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769 – 72 | en_US |
dc.identifier.citedreference | Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241 – 9. | en_US |
dc.identifier.citedreference | Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14 – 22. | en_US |
dc.identifier.citedreference | Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19: 1051 – 61. | en_US |
dc.identifier.citedreference | Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435 – 9. | en_US |
dc.identifier.citedreference | Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329: 948. | en_US |
dc.identifier.citedreference | Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161 – 72. | en_US |
dc.identifier.citedreference | Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388 – 91. | en_US |
dc.identifier.citedreference | Hutchison TA, Shahan DR, Anderson ML, eds. Drugdex® System. Englewood, CO: Micromedex Inc. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.